Nicola Ferrari’s Post

Fibrosis: cross-organ biology and pathways to development of innovative drugs This Review integrates viewpoints of biologists and physician-scientists on core pathways involved in fibrosis across organs, as well as on specific approaches to assess therapeutic interventions for fibrotic diseases of the lung, gut, kidney, skin and liver. - Fibrosis, which is a key characteristic of a range of chronic diseases, is the consequence of a dysregulated tissue repair response following injury. - The impact of fibrosis on morbidity and mortality worldwide is substantial. However, the only approved drugs that directly target fibrosis so far are pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF) and interstitial lung fibrosis. -  On the other hand, a long list of antifibrotic compounds with a wide range of putative mechanisms have failed to show benefit in clinical trials. - Fibrogenesis is complex, dynamic and multifactorial, and the expectation that targeting one single mechanism could fully prevent or treat this disease manifestation is likely to be naive. - Future antifibrotic approaches will probably address multiple parallel mechanisms simultaneously and require adaptation throughout the course of therapy based on biomarker profiles. https://lnkd.in/e-DgsVe5 #fibrosis #science #drugdevelopment